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Background: Behçet’s disease (BD) is a systemic inflammatory disease with manifestations including recurrent oral
and genital ulcerations, and vasculitis involving the skin, mucosa, joints, eyes, veins, arteries, nervous and
gastrointestinal systems. BD is seen as a disease at the crossroad between autoimmune and autoinflammatory
syndromes, possibly triggered by an aberrant response to infectious stimuli. The relevance of Gram negative
bacteria-mediated oral inflammation with the increased expression of NACHT, LRR, and PYD domains-containing
protein 3 (NLRP3), leading to systemic inflammation, prompted us to investigate the expression of NLRP3 inflammasome
components and its link with IL-1β hypersecretion.
Findings: When peripheral blood mononuclear cells (PBMCs) from 15 active, 15 stable BD patients and 15 healthy
volunteers were stimulated, the basal and LPS-induced expressions of NLRP3 inflammasome components were
significantly increased at both mRNA and protein levels in BD patients compared to healthy controls. Also, increased
expression of NLRP3 and ASC was observed in 25 BD skin lesions compared to 25 erythema nodosum patients.
Compatible with this, secretion of IL-1β by PBMCs stimulated with LPS alone or LPS plus ATP was increased in BD
compared to healthy controls, which was suppressed by caspase-1 inhibitor.
Conclusion: Our findings suggest the possible link between increased IL-1β secretion and increased expression of
NLRP3 inflammasome components in BD patients with skin manifestations.
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Behçet’s disease (BD) is a systemic inflammatory disease
with manifestations including recurrent oral and genital
ulcerations, and vasculitis involving the skin, mucosa,
joints, eyes, veins, arteries, nervous and gastrointestinal
systems. BD is currently seen as a disease at the crossroad
between autoimmune and autoinflammatory syndromes,
possibly triggered by an aberrant response to infectious
stimuli [1]. Oral microbial flora have long been implicated
in the pathogenesis of BD [2]. However, it is not clear
how infection induces an immune response and initiates
the development of BD. Recently it was shown that
NACHT, LRR, and PYD domains-containing protein 3
(NLRP3) inflammasome is upregulated when infected by* Correspondence: esl@ajou.ac.kr
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cases lead to induction and sustained aortic or gingival in-
flammation [3]. Also, peptidoglycan and LPS induced IL-
1β via the TLR2/4 and reactive oxygen species–NLRP3
inflammasome-dependent pathways in ocular BD [4]. As
oral ulcer precede BD for many years and EN like lesions,
one of most common skin manifestions in BD, which are
characterized by septal and lobular panniculitis and most
importantly vasculitis, we investigated whether NLRP3
inflammasome expression is increased at the mRNA and
protein levels in BD patients with skin manifestations.
Also, we studied whether IL-1β production was mediated
through NLRP3 inflammasome dependent pathway in BD.
Methods
Patients
Blood samples were taken from 15 active, 15 stable BD
patients and 15 healthy volunteers (HC) (Table 1). Allle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Characteristics of Behçet’s disease (BD) patients and
healthy controls
Demographics Active BD Inactive BD Healthy
control
Age (mean ± SD) 41.86 ± 7.54 43.6 ± 8.04 38.93 ± 6.94






Oral ulcer 15 (100)
Genital ulcer 10 (67)
Skin lesion 10 (67)
Ocular lesion 4 (27)
Minor symptoms
Arthritis 2 (13)
GI involvement 1 (7)
Epididymitis 0
Cardiovascular 1 (7)
CNS involvement 1 (7)
Medication
Immunosuppressive agenta 6 (40) 0 (0)
Anti-inflammatory drugsb 9 (60) 7 (46)
aMethylprednisolone 8–24 mg/d
bColchicine 1.2 mg/d ±minocycline 100 mg/d ± pentoxiphylline 800 mg/d ±
sulfasalazine 1000 mg/d
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selves for the first time or were monitored at the Depart-
ment of Dermatology, Ajou University Hospital. BD
patients met the Diagnostic criteria of the BD Research
Committee of Japan. The active group patients had at
least one of the BD symptoms despite the treatment and
inactive group patients were in well-controlled states. In-
formed consent was obtained prior to the study. This
study was approved by the Institutional Review Board (IRB
no.: AJIRB-GN3-07-098, AJIRB-GGEN-GEN-10-119).
Immunohistochemistry
Six mm punch skin biopsies of erythema nodosum
(EN)-like lesions of 25 BD and 25 EN patients were per-
formed. Formalin-fixed and paraffin-embedded tissues of
EN-like lesions in BD were cut (3-μm thickness) and
mounted onto slides. Specimens were deparaffinated and
endogenous peroxidase activity was blocked by 3 %
H2O2 in methanol for 15 min at room temperature.
After rinsing in phosphate-buffered saline (PBS) for
10 min, the nonspecific binding sites were blocked by
blocking solution for 10 min at room temperature and
all specimens were incubated with polyclonal antibodies
against NLRP3 (1:50 dilution, mouse, Alexis Biochemicals,
San diego, CA, USA) and ASC (1:100 dilution, rabbit,
Lifespan bioscience, Seattle, WA) for 30 min at roomtemperature. Next, HRP polymer (Thermo scientific,
Fremont, CA, USA) was applied and incubated for
30 min at room temperature. After washing in PBS for
10 min, bound antibodies were visualized by incubation
with AEC chromogen system (Thermo scientific, Fremont,
CA, USA). Slides were counterstained with hematoxylin.
Negative controls were isotype matched. The image was
analyzed using Image Pro Plus Version 4.5 (Media
Cybertics Co., MD, U.S.A.) (Additional file 1).
Quantitative real time PCR
Peripheral blood mononuclear cells (PBMCs) were pre-
pared from heparinized blood samples by Ficoll Hypaque
density gradients (Ficoll paqueTIM plus, StemCell Tech-
nologies, Vancouver, BC, Canada). PBMCs were stimu-
lated for 4 h with 100 ng/ml lipopolysaccharide (LPS;
Sigma-Aldrich). After 4 h, RPMI containing 1 mM ad-
enosine 5-triphosphate (ATP; Sigma-Aldrich) was added
to the cells for another 15 min (LPS/ATP). In separate
experiments, 20 μM zYVAD(Ome)-FMK an irreversible
caspase-1 inhibitor (CaspI; Enzo life science, Plymouth-
Meeting, PA) was added. The method for Quantitative
real time PCR is described in Additional file 2.
Western blotting
Briefly, freshly isolated PBMCs and stimulated PBMCs
were harvested and lysed in RIPA buffer (Sigma–Aldrich,
St. Louis, MO, USA) containing protease inhibitors. Cell
extracts were run on Bolt™ 4–12 % Bis–Tris Plus Gel (life
technologies, Carlsbad, CA, USA) and transferred onto
polyvinylidene difluoride membranes (Merck Milipore,
Darmstadt, Germany). Following transfer, the membrane
was blocked overnight at room temperature with PBS/
0.2 % Tween-20/5 % skim milk. Blots were incubated with
primary antibodies anti-NLRP3, anti-apoptosis-associated
speck-like protein containing a CARD (ASC), and anti-
caspase-1 antibodies (Abcam, Cambridge, MA). The
membranes were incubated in a solution containing an
appropriate secondary Ab (either anti-rabbit IgG or anti-
mouse IgG Ab) linked to horseradish peroxidase (Invitro-
gen). Bands were visualized with Immobilon Western
Chemiluminescent HRP Substrate (Merck Milipore,
Darmstadt, Germany) (Additional file 2).
ELISA for IL-1β
Total IL-1β and mature IL-1β level in the supernatants
was measured with a commercial ELISA kit from R&D
Systems according to the manufacturer’s protocols.
Statistics
The data are presented as mean ± standard deviation
(S.D.). Data were analyzed by one-way analysis of vari-
ance followed by the Scheffé test for overall multiple
comparisons among HC, stable BD, active BD. Student’s
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17.0 (SPSS Inc., Chicago, IL) was used. A p-value <0.05
was considered to indicate statistical significance.
Results and discussion
Previous reports show NLRP3 inflammasome expression
is increased in inflammatory diseases [5]. We investigated
the protein and mRNA levels of the different components
of NLRP3 inflammasomes, and NLRP1 for comparison.
The protein expression of NLRP3 inflammasome compo-
nents in PBMCs of BD patients was analyzed by western
blotting (Fig. 1a and b). The mean values of normalized
NLRP3, ASC and caspase-1 protein levels were signifi-
cantly up-regulated in active and stable BD compared with
HC. NLRP3, ASC and caspase-1 mRNA expression was
significantly up-regulated in active and stable BD com-
pared with HC (Fig. 1c). Next, we examined skin lesions
for in situ expression of NLRP3 and ASC to correlate ourFig. 1 The protein and mRNA expression of NLRP3, ASC, caspase-1 is incre
analysis (lane 1–3: healthy control, lane 4–6: stable BD, lane 7–9: active BD)
of freshly isolated PBMCs. β-actin was used as loading control (n = 5 per gr
measured from freshly isolated PBMCs by real time PCR and normalized ag
dehydrogenase. The relative values are shown as a fold change to HC with
skin lesions of BD patients and control EN lesions with anti-NLRP3 (left) and
inflammatory cells infiltrating the subcutaneous tissue (×200). Computer as
stained area in BD patients. The values are shown as a fold change to EN. T
are represented as mean ± S.D. (*p < 0.05), (−) no treatment. NLRP3: NACHT
mononuclear cells; HC: healthy volunteers; EN: erythema nodosumin vitro findings. NLRP3 and ASC in skin lesions of BD
and control EN patients were detected by immunohisto-
chemistry. NLRP3 and ASC was mostly expressed by
CD68+ macrophages/monocytes (Additional file 3). Image
analysis showed that NLRP3 and ASC expression was sig-
nificantly increased in BD skin lesions (Fig. 1d). These
findings show that mRNA and protein levels of NLRP3
inflammasome components are increased in BD patients.
Toll-like receptor signaling induces transcription of
NLRP3 and IL-1β [6, 7]. NLRP3 inflammasome is acti-
vated by canonical stimuli like ATP or Nigericin and
noncanonical stimuli like live gram negative bacteria [8].
Therefore, we checked whether LPS alone, or ATP
stimulation after LPS priming (LPS/ATP), affected the
expression of NLRP3 inflammasome components in
PBMCs of BD patients. The protein levels of, NLRP3,
ASC and caspase-1 were higher following LPS stimula-
tion compared to no stimulation in all the groups andased in Behçet’s disease (BD). a and b Representative western blot
and quantitation of NLRP1, NLRP3, ASC and caspase-1 from cell lysates
oup). c The mRNA expression of NLRP1, NLRP3, ASC and caspase-1 was
ainst the expression levels of glyceraldehyde 3-phosphate-
no treatment (n = 8 per group). d Immunohistochemistry staining of
anti-ASC (right) antibody showed NLRP3 and ASC expression in
sisted image analysis showed significant increase in NLRP3 and ASC
he smaller box is a magnified region (×400) (n = 25 per group). Data
, LRR, and PYD domains-containing protein 3; PBMCs: peripheral blood
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compared to HC (Fig. 2a). Following LPS/ATP stimula-
tion, NLRP3 and ASC protein levels were significantly
up-regulated only in active BD compared to HC (Fig. 2a).
The mRNA levels of, NLRP3, ASC and caspase-1 were
higher after LPS/ATP stimulation compared to single
stimulus of LPS in all the groups. Furthermore, they
were significantly increased in the presence of LPS or
LPS/ATP in active and stable BD compared to HC
(Fig. 2b). These findings show that LPS/ATP stimulation
resulted in significantly higher expression of NLRP3
inflammasome component at protein and mRNA levels
in PBMCs of BD patients.
To ascertain whether the increased NLRP3 inflamma-
some components might contribute to increased secre-
tion of IL-1β in BD, we assessed IL-1β secretion by
PBMCs stimulated with LPS or LPS/ATP (Fig. 3a and b)
In accordance with previous reports [7] showing that
peripheral blood monocytes stimulated with LPS release
ATP and consequently secrete IL-1β, treatment of
PBMCs with LPS alone increased IL-1β secretion com-
pared to no stimulation. This effect was suppressed by
caspase-1 inhibition and significantly higher in BD com-
pared to HC (Fig. 3a). Additionally, mature IL-1β secre-
tion in the presence of LPS/ATP was significantly
higher in active and stable BD than HC and suppressed
by caspase-1 inhibitor (Fig. 3b). There were significant
differences in LPS-induced and LPS/ATP-induced IL-1β
mRNA levels between BD and HC (Fig. 3c). However,
caspase-1 inhibitor suppressed mature IL-1β secretionFig. 2 The induced expression of NLRP3, ASC and caspase-1 is increased in
(100 ng/ml). After 4 h, ATP (1 mM) was added to the cells for another 15 m
of NLRP3, ASC and caspase-1 from cell lysates of stimulated PBMCs. β-actin
lane 3,6,9: LPS/ATP) (n = 5 per group). b The mRNA expression of NLRP3, AS
normalized against the expression levels of glyceraldehyde 3-phosphate-de
with no treatment (n = 8 per group). Data are represented as mean ± S.D. (
containing protein 3; PBMCs: peripheral blood mononuclear cells; LPS: lipopin the presence of LPS/ATP without a decrease in
mRNA levels (Fig. 3b and c). These findings suggest that
stimulation induced IL-1β expression and higher ex-
pression of NLRP3 inflammasome components in BD
might contribute to increased IL-1β secretion in BD
patients.
The hypothesis of an environmental trigger in BD
patients with genetic susceptibilities has long been advo-
cated [2]. These triggers range from infections to mo-
lecular mimicry such as heat-shock proteins (HSP),
which are synthesized under cellular stress. Inflamma-
somes are involved in both pathways of pathogen and
danger signal sensing, making it a good target for inves-
tigation in BD pathogenesis. Presence of a prolonged in-
flammation such as non-specific (pathergy) or urate
induced skin responses suggests that innate and adaptive
pathways are more integrated in BD [9]. The augmented
adaptive responses can be the result of persistant oral
and skin infections. Given the high frequency of oral
ulcer and the decrease of some symptoms with minocy-
cline, oral flora has been implicated in the pathogenesis
of BD [10, 11]. Recent studies have linked oral infection
to inflammasomes leading to sustained inflammation in
atherosclerosis [3]. In this study we showed that the
mRNA and protein levels of the NLRP3 inflammasome
were upregulated in PBMCs of BD patients and this was
further supported by in situ findings in skin lesions. This
may be a coincidental finding due to tissue damage and
release of DAMP, however the increase was more signifi-
cant compare to RAU, which also shows tissue damageBehçet’s disease (BD). PBMCs were initially stimulated for 4 h with LPS
in (LPS/ATP). a Representative western blot analysis and quantitation
was used as loading control. (lane 1,4,7: no treatment, lane 2,5,8: LPS,
C and caspase-1 was measured by real time quantitative RT-PCR and
hydrogenase. The relative values are shown as a fold change to HC
*p < 0.05), (−) no treatment. NLRP3: NACHT, LRR, and PYD domains-
olysaccharide; ATP: adenosine 5-triphosphate; HC: healthy volunteers
Fig. 3 Caspase-1 inhibits increase of IL-1β secretion by peripheral blood mononuclear cells (PBMCs) following NLRP3 activation. PBMCs were
initially stimulated for 4 h with LPS (100 ng/ml) with or without 20 μM zYVAD(Ome)-FMK, an irreversible caspase-1 inhibitor (LPS/CaspI). After 4 h,
ATP (1 mM) was added to the cells for another 15 min (LPS/ATP or LPS/ATP/CaspI). a Total IL-1β (n = 15 per group) and b mature processed
IL-1β (n = 9 per group) was quantitated in the supernatant of stimulated PBMCs by ELISA. c The mRNA expression of IL-1β was measured by real
time PCR and normalized against the expression levels of glyceraldehyde 3-phosphate-dehydrogenase. The relative values are shown as a fold
change to HC with no treatment (n = 8 per group). Data are represented as mean ± S.D. (*p < 0.05), (−) no treatment. PBMCs: peripheral blood
mononuclear cells; NLRP3: NACHT, LRR, and PYD domains-containing protein 3; LPS: lipopolysaccharide; ATP: adenosine 5-triphosphate
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somes may have a role in BD pathogenesis.
Pathways of inflammasome and pathogen-associated
molecular pattern such as toll-like receptors (TLRs)
intersect as both are sensors of bacterial products. We
have previously shown that TLR2 expression increases
at both the mRNA and protein levels, along with TLR4
expression at the mRNA level in active BD patients [12].
LPS from microorganisms could initiate IL-1β synthesis
process through TLRs and the inflammasomes. The
extracellular ATP released from stressed or infected cells
in oral tissue may further activate NLRP3 inflammasomes
leading to IL-1β maturation and release. The released IL-
1β can activate the release of other proinflammatory cyto-
kines. In this study we showed that the components of the
NLRP3 inflammasome pathway along with IL-1β mRNA
level were higher after LPS/ATP challenge compared to
LPS stimulation only in PBMCs of BD patients. The up-
regulation of components of the NLRP3 inflammasome
pathway along with IL-1β mRNA corresponded with in-
creased secretion of IL-1β. Also, IL-1β decreased when
caspase-1 inhibitor was added.
IL-1β synthesis, maturation, and secretion are tightly
regulated by Toll-like receptor (TLR) signaling and
inflammasome activation [13]. IL-1β has significant role
in BD pathomechanism. Specific IL-1β gene polymor-
phisms cause increased susceptibility to BD and IL-1β
blockade with recombinant anti-IL-1β antibody gevoki-
zumab has been used for BD treatment [14]. Thalido-
mide, an anti-inflammatory drug, used to treat BD, was
found to decrease IL-1β through caspase-1 inhibition
[15]. Therefore understanding the mechanism of NLRP3
in BD will not only help to elucidate their role in host
responses to infectious agents and to danger signals, but
may also contribute to the development of novel treat-
ment of BD.Conclusion
In this study, we showed that expression of NLRP3
inflammasome components were increased in BD PBMCs
and skin lesions. Also, IL-1β secretion was increased in
BD PBMCs when NLRP3 inflammasome components
were elevated and suppressed when caspase-1 inhibitor
was added. Our findings suggest the possible link between
increased IL-1β secretion and increased expression of
NLRP3 inflammasome components in BD patients with
skin manifestations.
Additional files
Additional file 1: Image analysis of immunohistochemical staining.
Image signals were recorded on a personal computer and evaluated
using Image Pro Plus Version 4.5 (Media Cybernetics Co., Silver Spring,
MD, USA). For each staining, we established a standard for antibody (Ab)
positivity and applied the same standards to the samples. The stained
area per total area was measured and the ratio of positive Ab area
(yellow) to the septal and lobular panniculitis area (green) was calculated.
Each measurement was evaluated under constant magnification (×200).
As inflammation presents mainly in and around the septa, fat lobules
were left out when calculating the area. The image analysis was
performed on a representative area of each specimen and repeated
three times by three examiners and the mean was used for evaluation.
Finally the data was expressed as fold difference between EN-like lesion
and EN.
Additional file 2: Detailed method for Quantitative real time PCR
and Western blotting.
Additional file 3: Erythema nodosum-like lesions are infiltrated with
CD3+ T lymphocytes, CD68+ monocytes and macrophages, and
Myeloperoxidase (MPO) + neutrophils. Immunohistologic staining was
performed on formalin-fixed and paraffin-embedded tissues of EN-like
lesions with a panel of antibodies directed against mononuclear cell
antigens using an indirect avidin-biotin immunoperoxidase technique.
The degree of inflammatory cell infiltration, which also showed positivity
to NLRP3 in serial section, were graded on a semi-quantitative scale of
0–4: 0, absent; 1, minimal; 2, mild; 3, moderate; 4, marked staining. All
slides were evaluated by three examiners in a blinded fashion and the
average score was calculated for each section. (A) anti-CD3 (1:200
dilution, mouse, Novocastra, Newcastle, UK), (B) anti-CD20 (1:300 dilution,
mouse, Dako, Denmark), (C) anti-CD68 (1:80 dilution, mouse, Novocastra,
Kim et al. Journal of Inflammation  (2015) 12:41 Page 6 of 6Newcastle, UK), (D) anti-MPO (1:600 dilution, rabbit, NeoMarker, Fremount,
CA, USA) antibody (×200) (n = 25). The semi-quantitative analysis of
inflammatory cell infiltration was as follows; CD3+ T lymphocytes: 2.01 ±
1.11, CD20+ B lymphocytes: 0.75 ± 1.05, CD68+ monocytes/macrophages:
3.14 ± 0.65, MPO+ neutrophils: 2.69 ± 1.27. Data are represented as
mean ± S.D.
Additional file 4: The induced expression of NLRP3, ASC, caspase-1
and IL-1β is increased in Behçet’s disease (BD) compared to healthy
control or recurrent apthous ulcer patients (RAU). PBMCs were
initially stimulated for 4 h with LPS (100 ng/ml) with or without 20 μM
zYVAD(Ome)-FMK, an irreversible caspase-1 inhibitor (LPS/CaspI). After
4 h, ATP (1 mM) was added to the cells for another 15 min (LPS/ATP or
LPS/ATP/CaspI). (A-D) The mRNA expression of NLRP3, ASC, caspase-1
and IL-1β was measured by real time quantitative RT-PCR and normalized
against the expression levels of glyceraldehyde 3-phosphate-
dehydrogenase. The relative values are shown as a fold change to HC
with no treatment (n = 8 per group). (E) Total IL-1β (n = 15 per group)
was quantitated in the supernatant of stimulated PBMCs by ELISA. Data
are represented as mean ± S.D. (*p < 0.05), (−): no treatment; LPS:
lipopolysaccharide; ATP: adenosine 5-triphosphate; CaspI: caspase-1
inhibitor; HC: healthy volunteers, RAU: Recurrent apthous ulcer (disease
control).
Abbreviations
ATP: Adenosine 5-triphosphate; BD: Behçet’s disease; EN: Erythema nodosum;
HC: Healthy volunteers; LPS: Lipopolysaccharide; RAU: Recurrent apthous
ulcer; NLRP3: NACHT, LRR, and PYD domains-containing protein 3;
PBMCs: Peripheral blood mononuclear cells; TLRs: Toll-like receptors.
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